Abstract
The mechanisms by which carbachol stimulates insulin release were studied in RINm5F cells. Stimulation was associated with mobilization of Ca2+ from thapsigargin-sensitive intracellular stores and elevation of the cytosolic Ca2+ concentration ([Ca2+]i). However, when the elevation of [Ca2+]i was blocked by prior treatment of the cells with thapsigargin or with the anticalmodulin agents W-7 or W-13, the effect of carbachol to stimulate insulin release was unchanged. Thus, the effect of carbachol to increase [Ca2+]i was dissociated from the stimulation of release. The role of protein kinase C (PKC) was next investigated. Carbachol-stimulated insulin release was unchanged by phorbol ester-induced down-regulation of PKC, at a time when the stimulation of release by 12-O-tetradecanoylphorbol-13-acetate was abolished. Similarly, when the effect of 12-O-tetradecanoylphorbol-13-acetate to stimulate release was blocked by each of three separate PKC inhibitors (staurosporine, bisindolylmaleimide, or 1-O-hexadecyl-2-O-methylglycerol), carbachol stimulated insulin release normally. Thus, the carbachol activation of PKC was also dissociated from the stimulation of insulin release. Finally, the effect of carbachol was examined in PKC-down-regulated cells in the simultaneous presence of thapsigargin. Carbachol still stimulated insulin release normally. It is concluded that carbachol stimulates insulin release in RINm5F cells by a novel mechanism that does not involve the elevation of [Ca2+]i or the activation of PKC. The action of carbachol appears to be exerted at a "distal site," beyond the point of increased [Ca2+]i, in stimulus-secretion coupling.
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|